Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Esophageal Squamous Cell Carcinoma 8Esophageal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Uterine Neoplasms 1Thyroid Neoplasms 1Thymoma 1Thymic epithelial tumor 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Mouth Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 34Carboplatin 27pembrolizumab 20Bevacizumab 16Letrozole 13Megestrol Acetate 10Cisplatin 9lenvatinib 8olaparib 7dostarlimab 7Metformin 7durvalumab 6abemaciclib 6Radiotherapy 6Everolimus 6niraparib 5Specimen Handling 5Nivolumab 5Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Biopsy 5temsirolimus 4rucaparib 4Oxaliplatin 4Fulvestrant 4Doxorubicin 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Neoplasms × TP protocol × Clear all
NCT06532539 2026-04-24

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
30 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡